A synthetic methylprostaglandin E1 analog that reduces gastric acid secretion and enhances the gastric mucus-bicarbonate barrier. It is effective in the therapy of gastric ulcers and gives significant protection against NSAID-induced gastric mucosal damage. The drug also prevents cyclosporin A-induced damage to endocrine and exocrine pancreatic secretions. It shows a low order of acute toxicity and there is no evidence of embryotoxicity, fetotoxicity, teratogenicity, or mutagenicity in animal studies.
Also Known As:
ORF-15927; RWJ-15927; TR-4698; ORF 15927; ORF15927; RWJ 15927; RWJ15927; TR 4698; TR4698; Prost-13-en-9-one, 1,11,16-trihydroxy-16-methyl-, (11alpha,13E)-
Networked: 45 relevant articles (14 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1. Duodenal Ulcer (Curling's Ulcer)
2. Stomach Ulcer (Gastric Ulcer)
3. Peptic Ulcer (Peptic Ulcers)
4. Ulcer
5. Pain (Aches)

Related Drugs and Biologics

1. Ranitidine (Zantac)
2. Alprostadil (Muse)
3. Enprostil
4. Misoprostol (Cytotec)
5. Cimetidine (Biomet)
6. Arbaprostil
7. trimoprostil
8. Uric Acid (Urate)
9. Insulin (Novolin)
10. Aspirin (Acetylsalicylic Acid)

Related Therapies and Procedures

1. Enteral Nutrition (Feeding, Tube)
2. Topical Administration